- MarketWatch•2 hours agoRoche Group's Genentech says Avastin with chemo has been approved for specific advanced ovarian cancer treatment
Roche Group's Genentech said Tuesday that its Avastin drug had been approved by the Food and Drug Administration to treat a specific type of advanced ovarian cancer in combination with chemotherapy. The ...
- Business Wire•2 hours agoFDA Approves Genentech’s Avastin® (Bevacizumab) Plus Chemotherapy for a Specific Type of Advanced Ovarian Cancer
Genentech, a member of the Roche Group , today announced that the U.S. Food and Drug Administration has approved Avastin® , either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.
- Forbes•2 hours ago
The year 2016 was a mixed one for Swiss pharmaceutical giant Roche . While the overall business improved on the back of the launch of new products and growth in the HER2+ drug franchise, the stock fell as investors remained cautious regarding broader industry factors. Overall, there was no change
RHHBY : Summary for ROCHE HLDGS AG SPN ADR EACH REP - Yahoo Finance
Roche Holding AG (RHHBY)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||27.50 - 27.81|
|52 Week Range||27.02 - 35.13|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||21.43|
|Dividend & Yield||1.02 (3.74%)|
|1y Target Est||N/A|